PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Iron Dextran→

Iron Dextran PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
9004-66-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Intravenous iron(III)-dextran complexparenteral iron replacement agent
Mechanism of action
A colloidal iron(III)-hydroxide core complexed with dextran. After administration, iron is taken up by reticuloendothelial cells and released for transferrin binding and incorporation into haemoglobin and iron stores; it is not a simple dissociating iron salt.
Indications / reported uses
  • Treatment of documented iron deficiency in adults and paediatric patients aged 4 months and older who cannot tolerate oral iron or have had an unsatisfactory response to oral iron; formulation-specific test-dose and hypersensitivity precautions apply

Sources: US DailyMed — INFeD (iron dextran) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Iron Dextran PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Iron Dextran Permitted Daily Exposure (PDE) report (the Iron Dextran PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Iron Dextran Occupational Exposure Limit (OEL) report (the Iron Dextran OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.